SMMT · Summit Therapeutics Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| GBP | — | — | — | — | — | — | — | 2.67M | -12.83M |
| $306.11M | $556.75M | $60.21M | $29.26M | $26.74M | $23.61M | $19.23M | — | — | |
| — | — | $0 | $0 | $914K | $1.02M | $1.25M | $1M | — | |
| GBP | — | — | — | — | — | — | — | 644K | 140K |
| $874.84M | $1.09B | $226M | $609.65M | $87.21M | $108.96M | $73.37M | — | — | |
| — | — | -$226M | -$609.65M | -$72.09M | -$86.19M | -$53.19M | — | — | |
| — | — | — | — | $1.51M | $0 | $4000 | — | — | |
| $18.76M | $14.84M | $13.37M | $11.18M | -$2.29M | -$2.42M | $283K | — | — | |
| -$856M | -$1.08B | -$221.15M | -$615.48M | -$78.48M | -$87.01M | -$51.73M | — | — | |
| USD/shares | -$1.11 | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | — | — |
| USD/shares | -$1.11 | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | — | — |
| shares | — | 747.7M | 718.54M | 619.65M | 193.34M | 131.71M | 69.52M | — | — |
| shares | — | 747.7M | 718.54M | 619.65M | 193.34M | 131.71M | 69.52M | — | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 121 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Reportable Segment | $0 | $0 | $705,000 |
By Geography (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Latin America | $705,000 | $1,809,000 | $860,000 | $662,000 |
| United States | — | — | $0 | $56,099,000 |
| Europe | — | — | — | $327,000 |
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| License And Service | $705,000 | $1,809,000 | $860,000 | $56,761,000 |
| Research Collaboration Agreements | — | — | — | $327,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Reportable Segment | -$225,998,000 | -$609,650,000 | -$72,089,000 |
Operating Margin by Segment (%)
| Component | FY2022 |
|---|---|
| Reportable Segment | -10225.4% |